Thermo Fisher Faces Challenging Market Dynamics
While Thermo Fisher is weathering the pullback in global biopharmaceutical spending and China softness better than most of its peers, it is still not immune to the overall softness in the life science market. Having an unmatched portfolio of products, resources, and manufacturing capabilities has allowed the firm to retain and grow its wallet share among its customers across all channels. We expect the current budget-constrained environment to stay suppressed throughout 2026. But long-term dynamics are still largely intact, and we see Thermo Fishe in a great position to leverage its share gains in the biopharma channel to capitalize on the eventual return of demand.
United States